Dashboard
Manage Tickers

AMRNAMARIN CORP PLC

Nasdaq www.amarincorp.com


$ 0.61 $ 0.00 (-0.36 %)    

Wednesday, 14-Aug-2024 15:59:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.96 $ 0.37 (0.08 %)
DIA $ 400.12 $ 2.33 (0.59 %)
SPY $ 543.85 $ 1.81 (0.33 %)
TLT $ 97.88 $ 0.60 (0.62 %)
GLD $ 226.19 $ -1.87 (-0.82 %)
$ 0.6122
$ 0.62
$ 0.61 x 900
-- x --
$ 0.61 - $ 0.62
$ 0.60 - $ 1.37
1,068,353
na
0
$ 1.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amarin-reiterates-for-fy24-it-believes-that-current-cash-and-investments-and-other-assets-are-adequate-to-support-continued-operations
Amarin Reiterates For FY24 It Believes Tha...
07/31/2024 11:06:09

amarin-corp-q2-2024-adj-eps-001-beats-004-estimate-sales-67500m-beat-51019m-estimate
Amarin Corp Q2 2024 Adj. EPS $0.01 Beats $...
07/31/2024 11:02:44

Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04) b...

hls-therapeutics-has-entered-into-a-product-listing-agreement-with-the-province-of-alberta-for-the-listing-and-public-reimbursement-of-amarins-vascepa-icosapent-ethyl-effective-august-1-2024
HLS Therapeutics Has Entered Into A Produc...
07/29/2024 10:50:32

Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by Alberta Health for the secondary preve...

portuguese-ministry-of-health-approves-vazkepa-for-national-reimbursement-to-reduce-cardiovascular-risk-in-high-risk-patients-eighth-national-reimbursement-in-europe-amarin-to-begin-commercialization-in-portugal-on-august-1-2024
Portuguese Ministry Of Health Approves VAZ...
07/17/2024 20:18:15

amarins-china-partner-eddingpharm-receives-regulatory-approval-from-nmpa-for-vascepa-in-mainland-china-for-cardiovascular-risk-reduction
Amarin's China Partner EddingPharm Receive...
07/08/2024 11:33:15

cantor-fitzgerald-reiterates-overweight-on-amarin-corp
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:21:36

Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.

cantor-fitzgerald-reiterates-overweight-on-amarin-corp
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 13:57:56

Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:AMRN) with a Overweight.

why-core--main-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Core & Main Shares Are Trading Lower B...
06/04/2024 16:54:09

amarin-has-appointed-aaron-berg-currently-amarins-executive-vice-president-and-president-of-the-us-business-as-president-and-chief-executive-officer-following-the-resignation-of-patrick-holt-as-president--ceo-of-the-company
Amarin Has Appointed Aaron Berg, Currently...
06/04/2024 11:32:30

amarin-corporation-announces-greek-ministry-of-health-approval-for-national-reimbursement-of-vazkepa-to-reduce-cardiovascular-events-in-high-risk-statin-treated-adults
Amarin Corporation Announces Greek Ministr...
05/28/2024 12:17:44

amarin-corp-q1-2024-adj-eps-001-beats-003-estimate-sales-56519m-miss-57045m-estimate
Amarin Corp Q1 2024 Adj EPS $(0.01) Beats ...
05/01/2024 11:03:47

Amarin Corp (NASDAQ:AMRN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) b...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 20:31:44

amarin-highlights-key-data-providing-mechanistic-insights-into-eicosapentaenoic-acid-at-acc24
Amarin Highlights Key Data Providing Mecha...
04/08/2024 12:23:14

Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity o...

reported-saturday-new-reduce-it-analyses-by-amarin-show-that-vascepavazkepa-benefits-high-risk-cardiovascular-disease-patient-subgroups
Reported Saturday, New REDUCE-IT Analyses ...
04/08/2024 07:04:17

amarin-received-decision-to-grant-from-european-patent-office-for-new-patent-covering-vazkepa-that-will-extend-vazkepa-exclusivity-eight-additional-years-into-2039
Amarin Received Decision To Grant From Eur...
04/03/2024 12:10:38

amarin-announces-research-evaluating-benefits-of-vascepavazkepa-to-be-presented-at-the-american-college-of-cardiologys-annual-scientific-session--expo
Amarin Announces Research Evaluating Benef...
03/25/2024 12:22:13

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the M...

why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Butterfly Network Shares Are Trading L...
02/29/2024 19:00:01

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

why-is-amarin-stock-trading-lower-after-q4-earnings
Why Is Amarin Stock Trading Lower After Q4...
02/29/2024 17:12:12

Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y...

amarin-continues-to-make-progress-on-reducing-operating-expenses-and-managing-its-cash-position
Amarin Continues To Make Progress On Reduc...
02/29/2024 12:17:19

amarin-says-initiated-shareholder-approval-process-to-execute-share-repurchase-program-of-up-to-50m-by-end-of-q2-2024
Amarin Says Initiated Shareholder Approval...
02/29/2024 12:16:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION